Curcumin Inhibits the Proteasome Activity in Human Colon Cancer Cells In vitro and In vivo
- 14 September 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (18), 7283-7292
- https://doi.org/10.1158/0008-5472.can-07-6246
Abstract
Curcumin (diferuloylmethane) is the major active ingredient of turmeric (Curcuma longa) used in South Asian cuisine for centuries. Curcumin has been shown to inhibit the growth of transformed cells and to have a number of potential molecular targets. However, the essential molecular targets of curcumin under physiologic conditions have not been completely defined. Herein, we report that the tumor cellular proteasome is most likely an important target of curcumin. Nucleophilic susceptibility and in silico docking studies show that both carbonyl carbons of the curcumin molecule are highly susceptible to a nucleophilic attack by the hydroxyl group of the NH2-terminal threonine of the proteasomal chymotrypsin-like (CT-like) subunit. Consistently, curcumin potently inhibits the CT-like activity of a purified rabbit 20S proteasome (IC50 = 1.85 μmol/L) and cellular 26S proteasome. Furthermore, inhibition of proteasome activity by curcumin in human colon cancer HCT-116 and SW480 cell lines leads to accumulation of ubiquitinated proteins and several proteasome target proteins, and subsequent induction of apoptosis. Furthermore, treatment of HCT-116 colon tumor–bearing ICR SCID mice with curcumin resulted in decreased tumor growth, associated with proteasome inhibition, proliferation suppression, and apoptosis induction in tumor tissues. Our study shows that proteasome inhibition could be one of the mechanisms for the chemopreventive and/or therapeutic roles of curcumin in human colon cancer. Based on its ability to inhibit the proteasome and induce apoptosis in both HCT-116 and metastatic SW480 colon cancer cell lines, our study suggests that curcumin could potentially be used for treatment of both early-stage and late-stage/refractory colon cancer. [Cancer Res 2008;68(18):7283–92]Keywords
This publication has 53 references indexed in Scilit:
- Curcumin enhances the effects of 5‐fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF‐1RInternational Journal of Cancer, 2007
- Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin?proteasome system and Cox-2Journal of Cellular and Molecular Medicine, 2007
- Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-κB and nuclear factor-κB–regulated gene products in IFN-α–sensitive and IFN-α–resistant human bladder cancer cellsMolecular Cancer Therapeutics, 2007
- Two distinct ubiquitin-dependent mechanisms are involved in NF-κB p105 proteolysisBiochemical and Biophysical Research Communications, 2006
- Antitumor Activity of Epidermal Growth Factor Receptor–Related Protein Is Mediated by Inactivation of ErbB Receptors and Nuclear Factor-κB in Pancreatic CancerCancer Research, 2006
- The Ubiquitin-Proteasome Pathway and Its Role in CancerJournal of Clinical Oncology, 2005
- Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosisFrontiers in Bioscience-Landmark, 2005
- Cleavage of Bax Enhances Its Cell Death FunctionExperimental Cell Research, 2000
- Influence of Piperine on the Pharmacokinetics of Curcumin in Animals and Human VolunteersPlanta Medica, 1998
- Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICENature, 1994